Bioanalysis accepted for coverage by EMBASE & Scopus

Future Science Ltd announces today that its journal Bioanalysis (ISSN 1757-6180) has been selected for coverage by both EMBASE & Scopus.

EMBASE is a premier online resource for biomedical literature, with over 24 million indexed records and more than 7,500 current, mostly peer-reviewed journals, EMBASE quickly and accurately delivers biomedical answers.
Scopus is the largest abstract and citation database of research literature and quality web sources covering nearly 18,000 titles from more than 5,000 publishers.

Bioanalysis is published fortnightly (24 issues per year), in print and online formats on a rapid publication basis, with articles subject to peer review by three independent assessors. The journal has an international expert authorship and offers commentary and analysis on the advances, implementation and performance of analytical technologies.

Coverage of the journal is directed by two Senior Editors and an extensive international advisory panel. The two Senior Editors are Brian Booth, Deputy Director, US FDA, Division of Clinical Pharmacology 5, USA and Howard Hill, Group Director Pharmaceutical Development, Huntingdon Life Sciences, UK.

The field of bioanalysis has matured significantly from early studies in drug metabolism using simple colorimetry. With the proliferation of sophisticated hyphenated techniques linking advanced separations with mass spectrometry and NMR as detection systems, automation and robotics, today's bioanalyst is well equipped to deal with the modern challenges of analyzing xenobiotics in biological matrices much faster and with a higher level of confidence. Furthermore, bioanalysts are now involved with the discovery, measurement and qualification of pharmacogenomic profiles and biomarkers and, subsequently, the development of diagnostic kits to individualize patient characterization and treatment.

Bioanalysis is a progressive discipline for which the future holds many exciting opportunities to further improve sensitivity, specificity, accuracy, efficiency, assay throughput, data quality, data handling and processing, analysis cost and environmental impact. Standards set by regulatory bodies regarding method development and validation increasingly define the boundaries between speed and quality. Bioanalysis the journal encourages the submission of any forward looking applications, including biosensors, microfluidics, miniaturized analytical devices, and new hyphenated and multi-dimensional techniques.

Howard Hill commented, “This is great news for the bioanalytical community. Bioanalysis fills an unmet niche and with wider coverage provided by EMBASE and Scopus, it will truly globalize its appeal. Bioanalysis will play a major role in the harmonization of both regulatory guidelines and science in the field of bioanalysis.”

Elisa Manzotti, Editorial Director of the Future Science series commented, “This specialized field has emerged as a real focus of attention in the past few years. We are delighted that Bioanalysis has been accepted for inclusion and will work with the Senior Editors of the journal to ensure that future issues of Bioanalysis keep pace with the huge amount of research being generated.” She continued: “We would like to thank our Senior Editors and Editorial Board for their hard work, intellectual input and guidance in targeting and evaluating topical, pioneering content to ensure inclusion of the journal by EMBASE and Scopus.”

Access to Bioanalysis is available on a FREE 30-day trial basis. To apply for your free trial please email [email protected] quoting reference: BIOPR211 to obtain password access.
For more information on Bioanalysis please visit: www.future-science.com.